ArticleInternational journal of retina and vitreous2017

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited.

Gary C Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.